Online inquiry

IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15732MR)

This product GTTS-WQ15732MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SEMA4D gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001142287.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10507
UniProt ID Q92854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15732MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ335MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ8499MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ12611MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ4912MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ5569MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ1808MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ10752MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ15249MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TAK-079
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW